Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for Gary D. Maynard
2.23
-0.03 (-1.11%)
Real-time:   1:47PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.21 - 2.29
52 week 1.88 - 3.68
Open 2.29
Vol / Avg. 177,812.00/512,727.00
Mkt cap 208.71M
P/E     -
Div/yield     -
EPS -0.57
Shares 92.14M
Beta 1.24
Inst. own 90%
Aug 2, 2016
Q2 2016 Rigel Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 9, 2016
Rigel Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
May 3, 2016
Q1 2016 Rigel Pharmaceuticals Inc Earnings Call - Webcast
May 3, 2016
Q1 2016 Rigel Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -347.27% -178.11%
Operating margin -349.31% -179.07%
EBITD margin - -174.09%
Return on average assets -58.37% -36.00%
Return on average equity -83.97% -46.86%
Employees 126 -
CDP Score - -

Address

1180 Veterans Blvd
SOUTH SAN FRANCISCO, CA 94080-1985
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).

Officers and directors

Raul R. Rodriguez President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ryan D. Maynard Chief Financial Officer and Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Donald G. Payan M.D. Executive Vice President, President - Discovery and Research, Director
Age: 66
Bio & Compensation  - Reuters
Anne-Marie Duliege M.D. Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Keith A. Katkin Director
Age: 43
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 60
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters